Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug could help 'Incompatible' kidney transplants succeed

NCT ID NCT07379957

Not yet recruiting Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests imlifidase, a drug that temporarily disables the immune system's antibodies, allowing highly sensitized patients to receive a kidney from a deceased donor they would otherwise reject. The trial will follow 450 patients in France to see how many get transplanted and how well the kidneys survive long-term. Early results suggest it can convert a positive crossmatch to negative in most patients, but antibody rejection and graft loss are still concerns.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Imlifidase (a drug that temporarily disables antibodies)
What this could lead to
If successful, this could help more highly sensitized patients get a kidney transplant and improve long-term graft survival.
What could go wrong
This is based on two small studies; antibody rejection and graft loss remain possible. Long-term data are still being collected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANTATION

Contacts and locations

Locations

  • CHU Amiens Picardie Site Sud

    Amiens, 80000, France

  • CHU Caen Normandie

    Caen, 14000, France

  • CHU Saint Etienne

    Saint-Etienne, 42000, France

  • CHU Tours Bretonneau

    Tours, 37000, France

  • CHU de Grenoble Alpes

    Grenoble, 38000, France

  • CHU de Nantes

    Nantes, 44000, France

  • CHU de Reims

    Reims, 51000, France

  • CHU de Strasbourg

    Strasbourg, 67000, France

  • Hôpital Bicêtre

    Paris, 75000, France

  • Hôpital Edouard Herriot

    Lyon, 69000, France

  • Hôpital Foch

    Suresnes, 92000, France

  • Hôpital Henri Mondor

    Créteil, 94000, France

  • Hôpital Huriez

    Lille, 59000, France

  • Hôpital Necker

    Paris, 75000, France

  • Hôpital Pasteur

    Nice, 06000, France

  • Hôpital Pellegrin

    Bordeaux, 33000, France

  • Hôpital Rangueil

    Toulouse, 31000, France

  • Hôpital Saint-Louis

    Paris, 75000, France

  • Hôpital de Bois-Guillaume

    Bois-Guillaume, 76000, France

  • Hôpital de la Conception

    Marseille, 13000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.